Device Trial Radar · NCT02145208
Study to Assess the Efficacy of Medi-Tate iTind Device
Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Oct 2014
Primary completion
Dec 2017
Study completion Nov 2021
Sponsor
- Lead sponsor
- Medi-Tate Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 22, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.
Conditions
- Benign Prostatic Hyperplasia (BPH)
Interventions
TIND SystemDevice
An implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- IPSSTime frame: 6 months.
- SAETime frame: 5-7 days
Locations
8 sites in 5 countries. Site status is shown where the registry gives one.
Edith Cavell
Brussels, Belgium
Gent Hospital University
Ghent, Belgium
San Orbessano
Turin, Italy
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.